Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...
Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...
CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...
CAMBRIDGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results